Cargando…
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
BACKGROUND: Modulation of the PD-1/PD-L1 axis through antagonist antibodies that block either receptor or ligand has been shown to reinvigorate the function of tumor-specific T cells and unleash potent anti-tumor immunity, leading to durable objective responses in a subset of patients across multipl...
Autores principales: | Li, Yiwen, Carpenito, Carmine, Wang, George, Surguladze, David, Forest, Amelie, Malabunga, Maria, Murphy, Mary, Zhang, Yiwei, Sonyi, Andreas, Chin, Darin, Burtrum, Douglas, Inigo, Ivan, Pennello, Anthony, Shen, Leyi, Malherbe, Laurent, Chen, Xinlei, Hall, Gerald, Haidar, Jaafar N., Ludwig, Dale L., Novosiadly, Ruslan D., Kalos, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925824/ https://www.ncbi.nlm.nih.gov/pubmed/29712568 http://dx.doi.org/10.1186/s40425-018-0329-7 |
Ejemplares similares
-
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018) -
High-content molecular profiling of T-cell therapy in oncology
por: Novosiadly, Ruslan, et al.
Publicado: (2016) -
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
por: Holmgaard, Rikke B., et al.
Publicado: (2018) -
Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition
por: Schaer, David, et al.
Publicado: (2015) -
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation
por: Shen, Yang, et al.
Publicado: (2015)